Inovio Pharmaceuticals Inc INO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INO is a good fit for your portfolio.
News
-
Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107
-
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024
-
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway
-
INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
-
INOVIO Reports Inducement Grant Under Inducement Plan
-
INOVIO Added to Russell 2000® Index Effective July 1, 2024
-
INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.
-
INOVIO Reports Inducement Grants Under Inducement Plan
Trading Information
- Previous Close Price
- $10.95
- Day Range
- $11.00–12.33
- 52-Week Range
- $3.89–14.75
- Bid/Ask
- $11.15 / $11.55
- Market Cap
- $293.31 Mil
- Volume/Avg
- 579,127 / 380,056
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 356.97
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 122
- Website
- https://www.inovio.com
Comparables
Valuation
|
Metric
|
INO
|
MRNA
|
002007
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 23.55 |
Price/Book Value | 2.80 | 3.65 | 2.56 |
Price/Sales | 356.97 | 9.16 | 5.67 |
Price/Cash Flow | — | — | 28.96 |
Price/Earnings
INO
MRNA
002007
Financial Strength
|
Metric
|
INO
|
MRNA
|
002007
|
|---|---|---|---|
Quick Ratio | 4.62 | 3.74 | 2.68 |
Current Ratio | 4.77 | 4.03 | 4.01 |
Interest Coverage | −120.76 | −148.54 | 140.38 |
Quick Ratio
INO
MRNA
002007
Profitability
|
Metric
|
INO
|
MRNA
|
002007
|
|---|---|---|---|
Return on Assets (Normalized) | −52.74% | −28.15% | 10.96% |
Return on Equity (Normalized) | −72.87% | −37.30% | 15.42% |
Return on Invested Capital (Normalized) | −65.03% | −36.39% | 12.13% |
Return on Assets
INO
MRNA
002007
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Sykfhckh | Wklm | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Bxhhccsn | Jnlcs | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rwwxrxnfn | Mblyj | $117.3 Bil | |||
| Moderna Inc
MRNA
| Zdbxlzrq | Mxnn | $46.1 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mzbtwmwn | Rrlkh | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Hqpqzrpls | Chsw | $28.8 Bil | |||
| BioNTech SE ADR
BNTX
| Qhcdzhb | Mxgq | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dptdfmcv | Hmjdkt | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Vghfgrgn | Kqbk | $15.0 Bil | |||
| Incyte Corp
INCY
| Xpvsnbwn | Hnfjqgq | $13.5 Bil |